International Journal of Science and Research Archive

eISSN: 2582-8185

Cross Ref DOI: 10.30574/ijsra

Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

Artificial intelligence in drug discovery and personalized medicine: Transforming the future of pharmaceutical research

Ahmed Hussein Abdalla Sagaf Mahfouz, Ahmed Indrakant Manilal Mathe *, Asim Osman Idriss Ali, Ahmed Omer Mohamed Ahmed and Ahmed Mohamed Mohamedali Gasmalla

Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research, K.R. Palli Cross, Anantapur, Chiyyedu, Andhra Pradesh-515721-India.

International Journal of Science and Research Archive, 2025, 14(02), 1394-1406

Publication history: Received on 08 January 2025; revised on 18 February 2025; accepted on 21 February 2025

Article DOI: https://doi.org/10.30574/ijsra.2025.14.2.0495

Abstract

The integration of artificial intelligence (AI) into drug discovery and personalized medicine has revolutionized the pharmaceutical industry by accelerating drug development and optimizing patient-specific treatments. Traditional drug discovery methods are often time-consuming, costly, and inefficient, with high attrition rates. AI-driven approaches leverage machine learning (ML), deep learning (DL), and big data analytics to streamline target identification, optimize lead compounds, and predict clinical outcomes with unprecedented accuracy. AI-based drug design, predictive analytics for pharmacokinetics, and toxicity assessment have significantly improved the efficiency of drug development pipelines. Furthermore, AI enables personalized medicine by analyzing multi-omics data, electronic health records, and real-world evidence to tailor treatments based on genetic, environmental, and lifestyle factors. Companies such as Atomwise, Insilico Medicine, and Tempus have demonstrated AI's potential in identifying novel drug targets and designing personalized treatment regimens. However, challenges such as data privacy, algorithmic bias, and regulatory compliance remain key obstacles to widespread adoption. This review provides a comprehensive overview of AI's role in transforming drug discovery and personalized medicine, addressing both its advantages and limitations while exploring future directions, including the integration of quantum computing and explainable AI. AI-driven innovations are poised to redefine pharmaceutical research, offering faster, safer, and more effective therapies for complex diseases.

Keywords: Artificial Intelligence in Drug Discovery; Personalized Medicine; Machine Learning in Pharmaceuticals; AI-Driven Drug Development; Predictive Analytics in Healthcare

1. Introduction

The history of drug discovery spans centuries, evolving from traditional herbal remedies to modern high-throughput screening and rational drug design. Early drug discovery relied heavily on serendipity and natural product isolation, as seen with the discovery of penicillin in 1928(1). The late 20th century introduced combinatorial chemistry and genomics, enabling the rapid synthesis and testing of thousands of compounds(2). However, these methods were often time-consuming, costly, and inefficient, with a high attrition rate in clinical trials(3). The 21st century marked a paradigm shift with the advent of artificial intelligence (AI), which has revolutionized the drug discovery pipeline(4). AI leverages machine learning (ML), deep learning (DL), and big data analytics to accelerate target identification, optimize drug candidates, and predict clinical outcomes(5). For instance, AI platforms like Atomwise and Insilico Medicine have demonstrated the ability to identify novel drug targets and design molecules in record time(6).

Parallel to this, personalized medicine has emerged as a critical approach to address individual variability in drug response, driven by genetic, environmental, and lifestyle factors(7). Traditional "one-size-fits-all" therapies often fail to

* Corresponding author: Ahmed Indrakant Manilal Mathe.

account for this variability, leading to suboptimal outcomes and adverse effects(8). Personalized medicine aims to tailor treatments based on an individual's unique genetic makeup, biomarkers, and clinical data(9). AI plays a pivotal role in this domain by analyzing vast datasets, including genomic, proteomic, and real-world evidence (RWE), to predict patient-specific responses and optimize therapeutic strategies(10). Together, AI-driven drug discovery and personalized medicine represent a transformative shift toward precision healthcare, promising faster, safer, and more effective treatments for complex diseases(11).

1.1. Scope of the Review

This review provides a comprehensive overview of the applications of AI in drug discovery and personalized medicine, highlighting its transformative potential and current limitations(12). In drug discovery, AI is being utilized across the entire pipeline, from target identification and validation to lead optimization and preclinical testing(13). For example, AI-driven platforms like BenevolentAI and Recursion Pharmaceuticals have successfully identified novel drug targets for rare diseases and optimized drug candidates with improved efficacy and safety profiles(14). Additionally, AI is being used to predict pharmacokinetics and toxicity, reducing the risk of late-stage clinical trial failures(15).

In personalized medicine, AI enables the integration of multi-omics data (genomics, transcriptomics, proteomics) with clinical and real-world data to develop tailored therapies(16). For instance, AI algorithms are being used to identify biomarkers for patient stratification, predict treatment responses, and design individualized treatment plans(17). Companies like Tempus and IBM Watson Health are leveraging AI to analyze electronic health records (EHRs) and genomic data, providing actionable insights for oncologists and other healthcare providers(18).

Despite these advancements, the field faces significant challenges, including data quality issues, algorithmic bias, and regulatory hurdles(19).This review also explores these challenges and discusses potential solutions, such as federated learning for data privacy and explainable AI (XAI) for model transparency(20).Furthermore, the review highlights emerging trends, including the integration of AI with decentralized clinical trials (DCTs) and the use of quantum computing for complex simulations(21).By addressing these topics, this review aims to provide a holistic understanding of AI's role in shaping the future of drug discovery and personalized medicine, offering insights into both its transformative potential and the barriers that must be overcome for widespread adoption(22).

2. AI in Drug Discovery

2.1. Target Identification and Validation

AI has become a game-changer in identifying and validating novel drug targets, particularly for complex diseases like rare genetic disorders and oncology(23).Traditional methods for target identification often rely on labor-intensive experimental approaches, which are time-consuming and costly(24). AI, however, can analyze vast datasets, including genomic, proteomic, and clinical data, to identify potential targets with high precision(25). For example, AI algorithms can detect disease-associated genes, pathways, and protein interactions by integrating multi-omics data(26). In rare diseases, where the patient population is small and data is scarce, AI's ability to uncover hidden patterns is particularly valuable(27). Platforms like **Atomwise** use deep learning to predict protein-ligand interactions, enabling the identification of novel targets for diseases such as Ebola and multiple sclerosis(28). Similarly, **BenevolentAI** employs AI to mine scientific literature and biomedical data, leading to the discovery of new targets for conditions like amyotrophic lateral sclerosis (ALS) and Parkinson's disease(29). In oncology, AI has been instrumental in identifying tumor-specific antigens and biomarkers, paving the way for targeted therapies and immunotherapies(30). For instance, AI-driven analyses have revealed new targets for glioblastoma and triple-negative breast cancer, offering hope for patients with limited treatment options(31). By accelerating target identification and validation, AI not only reduces the time and cost of drug discovery but also increases the likelihood of success in clinical trials(32).

Table 1 Applications of AI in Drug Discovery

Aspect	Description	Examples/Tools
Target Identification	AI analyzes genomic, proteomic, and clinical data to identify novel drug targets, especially for rare diseases and oncology.	Atomwise, BenevolentAI
Drug Design & Optimization	AI uses ML and DL to generate and optimize drug-like molecules, reducing time and cost.	Generative Adversarial Networks (GANs), Insilico Medicine, AtomNet

Predictive Analytics (ADMET)	AI predicts pharmacokinetics, toxicity, and drug-drug interactions to prioritize safe and effective compounds.	Schrödinger's AI platforms, DeepChem, ADMET Predictor

2.2. Drug Design and Optimization

The application of AI in drug design and optimization has transformed the way molecules are discovered and developed(33). Traditional drug design relies on trial-and-error methods, which are often inefficient and resource-intensive(33). AI, particularly machine learning (ML) and deep learning (DL), enables the rapid generation and optimization of drug-like molecules with desired properties(34). For example, generative adversarial networks (GANs) are being used for *de novo* drug design, where AI generates novel molecular structures that are optimized for specific targets(35).Companies like Insilico Medicine have demonstrated the power of GANs in designing molecules for fibrosis and cancer in a fraction of the time required by conventional methods(36). Another approach involves reinforcement learning, where AI iteratively improves molecular designs based on feedback from predictive models(37).Additionally, AI-driven platforms like AtomNet use convolutional neural networks (CNNs) to predict binding affinities, enabling the optimization of lead compounds(38).AI also facilitates the exploration of chemical space, identifying molecules with improved efficacy, selectivity, and safety profiles(39). For instance, AI has been used to redesign existing drugs for repurposing, such as identifying baricitinib as a potential treatment for COVID-19(40). By streamlining drug design and optimization, AI not only accelerates the discovery process but also reduces the risk of late-stage failures, making it a critical tool in modern pharmaceutical R&D(41).

2.3. Predictive Analytics for Pharmacokinetics and Toxicity

Predicting the pharmacokinetics (PK) and toxicity of drug candidates is a critical step in drug discovery, as poor ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties are a leading cause of clinical trial failures(42). AI has emerged as a powerful tool for predicting these properties, enabling researchers to prioritize compounds with favorable profiles early in the discovery process(43). Machine learning models are trained on large datasets of chemical structures and their corresponding ADMET properties, allowing them to predict how new compounds will behave in the body(44). For example, Schrödinger's AI-driven platforms use physics-based simulations and ML algorithms to predict solubility, bioavailability, and toxicity with high accuracy(45). Similarly, DeepChem and ADMET Predictor leverage deep learning to model complex relationships between molecular structures and their biological effects(46).AI is also being used to predict drug-drug interactions and off-target effects, which are critical for ensuring patient safety(47). For instance, AI models have been developed to identify potential cardiotoxic effects of drug candidates, reducing the risk of adverse events in clinical trials(48). By integrating predictive analytics into the drug discovery pipeline, AI enables researchers to make data-driven decisions, optimizing lead compounds for both efficacy and safety(49). This not only reduces the cost and time of drug development but also increases the likelihood of success in later stages, ultimately bringing safer and more effective therapies to patients faster(50).

3. Personalized Medicine and AI

3.1. Genomic Data Integration

AI has revolutionized the integration of genomic, transcriptomic, and proteomic data, enabling the development of highly personalized therapies(51). By analyzing large-scale biological datasets, AI can identify genetic mutations, gene expression patterns, and protein interactions that drive disease progression. This information is critical for tailoring treatments to individual patients, particularly in complex diseases like cancer. For example, IBM Watson for Oncology uses AI to analyze genomic data from tumor samples and match patients with targeted therapies based on their unique genetic profiles. Similarly, Tempus leverages AI to integrate genomic and clinical data, providing oncologists with actionable insights for treatment decisions(52). AI also plays a key role in identifying therapeutic targets in rare genetic disorders, where traditional methods often fall short. For instance, AI-driven analyses have identified novel gene targets for conditions like Duchenne muscular dystrophy and cystic fibrosis, paving the way for gene therapies and precision treatments. By integrating multi-omics data, AI not only enhances our understanding of disease mechanisms but also enables the development of therapies that are tailored to the molecular characteristics of each patient, improving outcomes and reducing adverse effects.

3.2. Patient Stratification and Biomarker Discovery

AI is transforming patient stratification and biomarker discovery by enabling the identification of subgroups of patients who are most likely to respond to specific treatments(53). This is particularly important in diseases like cancer, where heterogeneity in tumor biology often leads to variable treatment responses. AI algorithms can analyze complex datasets, including genomic, proteomic, and clinical data, to identify biomarkers that predict treatment efficacy and disease

progression. For example, in cancer immunotherapy, AI has been used to identify biomarkers such as tumor mutational burden (TMB) and PD-L1 expression, which are associated with response to immune checkpoint inhibitors. Companies like Foundation Medicine use AI to analyze tumor genomes and provide biomarker-driven treatment recommendations(54). In rare genetic disorders, AI has enabled the discovery of biomarkers for conditions like spinal muscular atrophy (SMA) and Huntington's disease, facilitating early diagnosis and targeted interventions. AI-driven biomarker discovery also extends to non-oncological conditions, such as cardiovascular diseases and neurodegenerative disorders, where it helps identify patients at risk of disease progression. By enabling precise patient stratification, AI ensures that therapies are directed to those who will benefit the most, improving clinical outcomes and optimizing resource utilization(55).

3.3. Real-World Data (RWD) and Real-World Evidence (RWE)

The integration of real-world data (RWD) and real-world evidence (RWE) into personalized medicine is being revolutionized by AI(56). RWD includes data from electronic health records (EHRs), wearable devices, patient registries, and social determinants of health, providing a comprehensive view of patient health outside controlled clinical trial settings. AI algorithms can analyze this data to identify patterns, predict outcomes, and inform personalized treatment plans. For example, AI-driven analysis of EHRs has been used to predict hospital readmissions, optimize medication regimens, and identify patients at risk of adverse drug reactions. Wearable devices, such as smartwatches and fitness trackers, generate continuous streams of data on vital signs, physical activity, and sleep patterns, which AI can analyze to monitor chronic conditions and adjust treatments in real time(57). Companies like Apple and Fitbit are collaborating with healthcare providers to integrate wearable data into personalized care plans. AI also enables the aggregation and analysis of RWE from diverse sources, providing insights into the long-term effectiveness and safety of therapies in real-world populations. For instance, AI has been used to analyze RWE from cancer registries to identify factors associated with treatment response and survival(58). By leveraging RWD and RWE, AI bridges the gap between clinical trials and real-world practice, enabling more personalized, data-driven healthcare that improves patient outcomes and reduces costs.

Table 2 AI in Personalized Medicine

Aspect	Description	Examples/Tools
Genomic Data Integration	AI integrates genomic, transcriptomic, and proteomic data to tailor therapies for individual patients.	IBM Watson for Oncology, Tempus
Patient Stratification	AI identifies biomarkers to stratify patients and predict treatment responses, especially in cancer and rare diseases.	Foundation Medicine
Real-World Data (RWD) & Evidence (RWE)	AI analyzes EHRs, wearable data, and patient registries to inform personalized treatment plans.	Apple, Fitbit, Medable, Science 37

4. AI in Clinical Trials

4.1. Trial Design and Recruitment

AI is revolutionizing the design and recruitment processes for clinical trials, addressing some of the most significant challenges in drug development. Traditional trial design often relies on static protocols that may not account for patient variability or emerging data, leading to inefficiencies and high dropout rates. AI enables the optimization of trial protocols by analyzing historical trial data, patient demographics, and disease characteristics to design more flexible and adaptive trials(59). For example, AI can identify the most effective dosing regimens, endpoints, and inclusion/exclusion criteria, improving the likelihood of trial success.

In recruitment, AI-powered platforms like Deep 6 AI and Antidote are transforming how eligible participants are identified. These tools analyze electronic health records (EHRs), medical claims, and patient registries to match individuals with clinical trials based on their medical history, genetic profiles, and lifestyle factors. For instance, Deep 6 AI uses natural language processing (NLP) to extract relevant information from unstructured clinical notes, enabling researchers to quickly identify potential participants. Similarly, Antidote's AI-driven platform connects patients with trials through an intuitive interface, streamlining the recruitment process. By reducing the time and cost associated with trial design and recruitment, AI is helping to bring new therapies to market faster and more efficiently(14).

4.2. Predictive Modeling for Trial Outcomes

AI's ability to predict clinical trial outcomes is transforming the way trials are conducted, reducing the risk of failure and improving resource allocation. Predictive modeling uses machine learning (ML) algorithms to analyze data from previous trials, patient characteristics, and real-world evidence (RWE) to forecast how patients will respond to experimental treatments. This enables researchers to identify potential issues early, such as low efficacy or safety concerns, and adjust trial protocols accordingly(60).

A notable example is the use of AI in adaptive trial designs, where trial parameters are modified in real time based on interim results. For instance, AI has been used in oncology trials to predict patient responses to immunotherapies, allowing researchers to adjust dosing or switch therapies for non-responders. Companies like **Unlearn.AI** are leveraging AI to create digital twins—virtual replicas of patients—that simulate how individuals might respond to treatments, enabling more accurate predictions of trial outcomes. By incorporating predictive modeling into clinical trials, AI not only reduces the risk of failure but also enhances the efficiency and ethical conduct of research, ensuring that patients receive the most effective treatments(61).

4.3. Decentralized Clinical Trials (DCTs)

Decentralized clinical trials (DCTs), which rely on remote monitoring and virtual tools, are being significantly enhanced by AI(62). DCTs aim to make clinical research more accessible by reducing the need for patients to visit trial sites, which is particularly beneficial for those with mobility issues or living in remote areas. AI plays a critical role in managing DCTs by enabling remote data collection, real-time monitoring, and patient engagement(63).

For example, AI-powered wearable devices can continuously collect data on vital signs, physical activity, and medication adherence, providing researchers with a comprehensive view of patient health. Platforms like Medable and Science 37 use AI to analyze this data, ensuring that trials remain on track and that any adverse events are quickly identified(63). AI also facilitates virtual patient interactions through chatbots and telehealth platforms, improving communication and retention rates. Additionally, AI-driven analytics can identify trends and anomalies in remote data, enabling researchers to make data-driven decisions without compromising trial integrity. By leveraging AI, DCTs are becoming more efficient, patient-centric, and scalable, paving the way for a new era of clinical research that prioritizes accessibility and inclusivity(57).

5. Ethical and Regulatory Considerations

5.1. Data Privacy and Security

The use of AI in drug discovery and personalized medicine relies heavily on sensitive patient data, including genomic information, electronic health records (EHRs), and real-world evidence (RWE). This raises significant concerns about data privacy and security, as breaches can lead to misuse of personal information and loss of patient trust(64). Challenges include ensuring compliance with regulations like the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., which mandate strict controls over how patient data is collected, stored, and shared(65).

To address these challenges, innovative solutions like federated learning and blockchain are being adopted. Federated learning allows AI models to be trained across multiple decentralized devices or servers without transferring raw data, preserving privacy. For example, Google's federated learning framework has been used in healthcare to develop predictive models while keeping patient data localized(66). Blockchain, on the other hand, ensures data integrity and traceability by creating immutable records of data transactions. Companies like Hashed Health are exploring blockchain for secure sharing of clinical trial data. These technologies not only enhance data security but also enable collaboration across institutions, fostering innovation while safeguarding patient privacy(67).

5.2. Bias and Fairness in AI Models

Algorithmic bias is a critical issue in AI-driven drug discovery and personalized medicine, as biased models can lead to inequitable healthcare outcomes. Bias can arise from unrepresentative training datasets, flawed algorithms, or unintended correlations in the data(68). For example, if a dataset predominantly includes genomic data from individuals of European descent, AI models may perform poorly for other ethnic groups, exacerbating health disparities. Similarly, biased models in clinical trials may exclude certain populations, limiting the generalizability of findings(69).

To address bias, researchers are adopting strategies such as diverse dataset curation, algorithmic fairness techniques, and bias audits. Diverse datasets ensure that AI models are trained on representative samples, while fairness-aware algorithms adjust for imbalances in the data(70). For instance, IBM's AI Fairness 360 toolkit provides tools to detect and mitigate bias in machine learning models. Additionally, regulatory bodies are emphasizing the need for transparency and accountability in AI development, requiring developers to document data sources, model assumptions, and validation processes(71). By prioritizing fairness, the healthcare community can ensure that AI-driven innovations benefit all populations equitably(72).

5.3. Regulatory Frameworks

The rapid adoption of AI in drug discovery and personalized medicine has prompted regulatory agencies to develop guidelines for its safe and effective use. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have taken proactive steps to regulate AI-based technologies(73). For example, the FDA's Digital Health Innovation Action Plan and Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan provide frameworks for evaluating AI-driven tools(74). Similarly, the EMA has issued guidelines on the use of AI in clinical trials and drug development, emphasizing the need for robust validation and transparency(75).

However, the global regulatory landscape remains fragmented, with varying standards across regions. To address this, there is a growing call for harmonized regulations that facilitate international collaboration while ensuring patient safety(76). Future directions include the development of standardized validation protocols, real-world performance monitoring, and adaptive regulatory pathways that keep pace with technological advancements. For instance, the FDA's Breakthrough Devices Program fast-tracks innovative technologies, including AI-driven tools, by providing expedited review and iterative feedback(77). By fostering a collaborative and adaptive regulatory environment, policymakers can support the responsible integration of AI into healthcare, ensuring that innovations are both safe and effective for patients worldwide(78).

6. Challenges and Limitations

6.1. Data Quality and Availability

One of the most significant challenges in leveraging AI for drug discovery and personalized medicine is ensuring the quality and availability of data(12). AI models rely on large, high-quality datasets to make accurate predictions, but such datasets are often incomplete, fragmented, or biased(79). For example, genomic data may be skewed toward specific populations, leading to models that perform poorly for underrepresented groups(80). Similarly, real-world data (RWD) from electronic health records (EHRs) can be inconsistent or lack standardization, making it difficult to train reliable AI models(81).

Efforts to address these issues include data harmonization initiatives, such as the Observational Health Data Sciences and Informatics (OHDSI) program, which standardizes EHR data for research(82). Additionally, collaborations between academia, industry, and healthcare providers are helping to pool data resources and improve dataset diversity(83). However, challenges remain in ensuring data privacy and overcoming legal and ethical barriers to data sharing. Without high-quality, representative datasets, the potential of AI in healthcare cannot be fully realized(84).

6.2. Interpretability of AI Models

The "black box" nature of many AI models poses a significant challenge in drug discovery and personalized medicine(85). Complex algorithms, such as deep neural networks, often produce highly accurate predictions but lack transparency in how those predictions are made. This lack of interpretability can hinder trust among clinicians, regulators, and patients, particularly when AI-driven decisions impact patient care(86). For example, if an AI model recommends a specific treatment, clinicians need to understand the rationale behind the recommendation to ensure it aligns with medical knowledge and patient needs(87).

To address this, researchers are developing explainable AI (XAI) techniques that provide insights into model decision-making. Tools like LIME (Local Interpretable Model-agnostic Explanations) and SHAP (SHapley Additive exPlanations) help break down complex models into interpretable components(88). Regulatory agencies are also emphasizing the importance of transparency, requiring AI developers to document model architectures, training data, and validation processes. Despite these efforts, achieving a balance between model complexity and interpretability remains a key challenge in the field(89).

6.3. Integration with Existing Workflows

Integrating AI into traditional pharmaceutical research and development (R&D) workflows presents several barriers(90). Many pharmaceutical companies rely on established processes and legacy systems that are not designed to accommodate AI-driven approaches(91). For example, AI tools for drug discovery often require specialized infrastructure, such as high-performance computing (HPC) resources, which may not be readily available in traditional labs. Additionally, there is often resistance to change from stakeholders who are accustomed to conventional methods(92).

To overcome these barriers, companies are investing in digital transformation initiatives that modernize R&D workflows and foster a culture of innovation. For instance, Pfizer and Novartis have established AI-focused teams and partnerships with tech companies to integrate AI into their pipelines(93). Training programs and cross-disciplinary collaborations are also helping to bridge the gap between data scientists and traditional researchers(94). However, the integration process is complex and requires significant investment in both technology and human resources. Without seamless integration, the full potential of AI in accelerating drug discovery and improving patient outcomes cannot be realized(95).

7. Future Directions

7.1. Emerging Technologies

The future of AI in drug discovery and personalized medicine is being shaped by emerging technologies such as quantum computing and explainable AI (XAI). Quantum computing, with its ability to perform complex calculations at unprecedented speeds, holds the potential to revolutionize molecular modeling and simulation(96). For example, quantum algorithms could enable the accurate prediction of protein-ligand interactions, accelerating the discovery of new drug candidates. Companies like Google Quantum AI and IBM Quantum are already exploring applications in chemistry and materials science, paving the way for breakthroughs in pharmaceutical research(97).

Explainable AI (XAI) is another critical area of development, addressing the "black box" problem by making AI models more transparent and interpretable(98). Techniques like SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) are being used to provide insights into how AI models make decisions, fostering trust among clinicians and regulators and understandable. . As these technologies mature, they will enable more reliable and ethical AI applications in healthcare, ensuring that AI-driven decisions are both accurate(99).

7.2. Collaborative Ecosystems

The future of AI in healthcare will depend on robust collaborative ecosystems that bring together pharmaceutical companies, tech firms, academic institutions, and regulatory bodies. Partnerships between these stakeholders are essential for pooling resources, sharing expertise, and accelerating innovation(100). For example, Pfizer has partnered with IBM Watson Health to use AI for cancer drug discovery, while Novartis collaborates with Microsoft to develop AI-driven solutions for clinical trials(101).

Academic institutions play a crucial role in advancing foundational research and training the next generation of AI experts. Initiatives like the MIT-IBM Watson AI Lab and the Stanford AI in Healthcare Program are fostering interdisciplinary research and innovation(102). Regulatory bodies are also engaging with industry and academia to develop guidelines for AI in healthcare, ensuring that innovations are safe and effective(103). By fostering collaboration, these ecosystems will drive the development of cutting-edge AI tools and ensure their responsible integration into healthcare(104).

7.3. Global Health Applications

AI has the potential to address unmet medical needs in low-resource settings, where access to healthcare is often limited. For example, AI-powered diagnostic tools can analyze medical images or patient data to detect diseases like tuberculosis, malaria, and diabetic retinopathy, even in the absence of specialized healthcare providers(105). Companies like Zebra Medical Vision and Butterfly Network are developing affordable, portable AI-driven devices that can be used in remote or underserved areas(106).

AI can also support public health initiatives by predicting disease outbreaks, optimizing resource allocation, and improving vaccine distribution. For instance, AI models have been used to track the spread of COVID-19 and identify

high-risk populations(107). In addition, AI-driven telemedicine platforms are expanding access to healthcare in rural and low-income regions, enabling patients to consult with doctors remotely(108).

By leveraging AI to address global health challenges, the healthcare community can reduce disparities and improve outcomes for underserved populations. However, this will require investments in infrastructure, training, and partnerships with local stakeholders to ensure that AI solutions are culturally appropriate and sustainable(109). The future of AI in global health lies in its ability to democratize access to high-quality care and empower communities to take control of their health(110).

8. Conclusion

AI has emerged as a game-changer in drug discovery and personalized medicine, driving efficiency, precision, and innovation. By leveraging ML, DL, and big data analytics, AI accelerates the identification of drug targets, optimizes molecular design, and enhances predictive modeling for pharmacokinetics and toxicity. These advancements significantly reduce the time and cost associated with traditional drug development while improving the likelihood of clinical success. In personalized medicine, AI facilitates the integration of genomic, proteomic, and real-world data to tailor treatments for individual patients, ensuring better therapeutic outcomes and minimizing adverse effects. Despite these advancements, challenges such as data quality, algorithmic bias, regulatory constraints, and ethical considerations must be addressed for AI's full potential to be realized. Efforts toward explainable AI (XAI), federated learning for data privacy, and regulatory harmonization are crucial in overcoming these barriers. Future directions, including the incorporation of quantum computing and AI-driven decentralized clinical trials, hold great promise for advancing drug discovery and precision medicine. As AI technologies continue to evolve, collaboration among pharmaceutical companies, regulatory bodies, and healthcare providers will be essential in ensuring responsible and effective implementation. Ultimately, AI is poised to redefine pharmaceutical research, bringing forth innovative, patient-centric solutions for complex diseases.

Compliance with ethical standards

Acknowledgments

Authors are extremely thankful to Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh-India

Disclosure of conflict of interest

The authors do not have any conflict of interest.

References

[1] Pina AS, Hussain A, Roque ACA. An historical overview of drug discovery. Ligand-Macromolecular Interactions in Drug Discovery: Methods and Protocols. 2010:3-12.

[2] Liu R, Li X, Lam KS. Combinatorial chemistry in drug discovery. Current opinion in chemical biology. 2017;38:117-26.

[3] Mahajan R, Gupta K. Adaptive design clinical trials: Methodology, challenges and prospect. Indian journal of pharmacology. 2010;42(4):201-7.

[4] Husnain A, Rasool S, Saeed A, Hussain HK. Revolutionizing pharmaceutical research: harnessing machine learning for a paradigm shift in drug discovery. International Journal of Multidisciplinary Sciences and Arts. 2023;2(2):149-57.

[5] Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010.

[6] Lee D. AI-Driven Drug Discovery and Development for Precision Medicine. African Journal of Artificial Intelligence and Sustainable Development. 2023;3(1):1-11.

[7] Naylor S, Chen JY. Unraveling human complexity and disease with systems biology and personalized medicine. Personalized medicine. 2010;7(3):275-89.

[8] Rini CS, Fitriana FW, Purwoko RY, Librianty N, Lundeto A. Personalized Medicine: Leveraging Genomics for Tailored Treatment Approaches. The Journal of Academic Science. 2024;1(5):553-61.

[9] Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Translational research. 2009;154(6):277-87.

[10] Gangwal A, Lavecchia A. AI-Driven Drug Discovery for Rare Diseases. Journal of Chemical Information and Modeling. 2024.

[11] Fatima G, Siddiqui Z, Parvez S. AI and Precision Medicine: Paving the Way for Future Treatment. 2024.

[12] Taherdoost H, Ghofrani A. AI and the Evolution of Personalized Medicine in Pharmacogenomics. Intelligent Pharmacy. 2024.

[13] Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nature Medicine. 2025:1-15.

[14] Bhatt P, Singh S, Kumar V, Nagarajan K, Mishra SK, Dixit PK, et al. Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery. Current Artificial Intelligence. 2024;2(1):E051223224198.

[15] Jain R, Subramanian J, Rathore AS. A review of therapeutic failures in late-stage clinical trials. Expert Opinion on Pharmacotherapy. 2023;24(3):389-99.

[16] Mohr AE, Ortega-Santos CP, Whisner CM, Klein-Seetharaman J, Jasbi P. Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines. 2024;12(7):1496.

[17] Jain N, Nagaich U, Pandey M, Chellappan DK, Dua K. Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements. EPMA Journal. 2022;13(4):561-80.

[18] Gao X, He P, Zhou Y, Qin X. Artificial Intelligence Applications in Smart Healthcare: A Survey. Future Internet. 2024;16(9):308.

[19] Aldoseri A, Al-Khalifa KN, Hamouda AM. Re-thinking data strategy and integration for artificial intelligence: concepts, opportunities, and challenges. Applied Sciences. 2023;13(12):7082.

[20] Rahman A, Hossain MS, Muhammad G, Kundu D, Debnath T, Rahman M, et al. Federated learning-based AI approaches in smart healthcare: concepts, taxonomies, challenges and open issues. Cluster computing. 2023;26(4):2271-311.

[21] Ye J, Nie L. Operation and Other Considerations. Innovative Designs and Analyses for Small Population Clinical Trials: Development Strategies and Operational Engagement for Pediatric and Rare Diseases: Springer; 2024. p. 419-58.

[22] Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics. 2024;16(10):1328.

[23] Fatima MJ, Parthiban C. Artificial Intelligence [AI]-The Game Changer in Pharmaceutical Industry. Asian Journal of Pharmacy and Technology. 2024;14(4).

[24] Ziegler S, Pries V, Hedberg C, Waldmann H. Target identification for small bioactive molecules: finding the needle in the haystack. Angewandte Chemie International Edition. 2013;52(10):2744-92.

[25] Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology. 2022;39(8):120.

[26] Chen C, Wang J, Pan D, Wang X, Xu Y, Yan J, et al. Applications of multi-omics analysis in human diseases. MedComm. 2023;4(4):e315.

[27] Lyroi E, Olusegun J, Amizu T, Tayo O. AI in Rare Disease Diagnosis: Solving the Puzzle of Complex Cases. 2025.

[28] Khinvasara T. Revolutionizing Drug Discovery: Harnessing Machine Learning Algorithms.

[29] Singh A. Artificial intelligence for drug repurposing against infectious diseases. Artificial Intelligence Chemistry. 2024;2(2):100071.

[30] Kumar A, Dixit S, Srinivasan K, Vincent PDR. Personalized cancer vaccine design using AI-powered technologies. Frontiers in Immunology. 2024;15:1357217.

[31] Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, et al. Revolutionizing cancer treatment: recent advances in immunotherapy. Biomedicines. 2024;12(9):2158.

[32] Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug discovery today. 2019;24(3):773-80.

[33] Jing Y, Bian Y, Hu Z, Wang L, Xie X-QS. Deep learning for drug design: an artificial intelligence paradigm for drug discovery in the big data era. The AAPS journal. 2018;20:1-10.

[34] Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R, et al. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antiviral Research. 2023:105740.

[35] Tong X, Liu X, Tan X, Li X, Jiang J, Xiong Z, et al. Generative models for de novo drug design. Journal of Medicinal Chemistry. 2021;64(19):14011-27.

[36] Gangwal A, Lavecchia A. Unlocking the potential of generative AI in drug discovery. Drug Discovery Today. 2024:103992.

[37] Son A, Park J, Kim W, Yoon Y, Lee S, Park Y, et al. Revolutionizing Molecular Design for Innovative Therapeutic Applications through Artificial Intelligence. Molecules. 2024;29(19):4626.

[38] Singh S, Kaur N, Gehlot A. Application of artificial intelligence in drug design: A review. Computers in Biology and Medicine. 2024;179:108810.

[39] Gangwal A, Lavecchia A. Artificial Intelligence in Natural Product Drug Discovery: Current Applications and Future Perspectives. Journal of Medicinal Chemistry. 2025.

[40] Basu S, Shafi J. Topical Repute on Artificial Intelligence-Based Approaches in COVID-19 Supervision: Distinct Kingpin on Drug Re-Purposing Blueprint. Principles and Methods of Explainable Artificial Intelligence in Healthcare: IGI Global; 2022. p. 180-210.

[41] Sharma A, Mittal K, Arora D, Ganti SS. A comprehensive review on strategies for new drug discovery and enhanced productivity in research and development: recent advancements and future prospectives. Mini-Reviews in Organic Chemistry. 2021;18(3):361-82.

[42] Pantaleão SQ, Fernandes PO, Gonçalves JE, Maltarollo VG, Honorio KM. Recent advances in the prediction of pharmacokinetics properties in drug design studies: a review. ChemMedChem. 2022;17(1):e202100542.

[43] Udegbe FC, Ebulue OR, Ebulue CC, Ekesiobi CS. Machine Learning in Drug Discovery: A critical review of applications and challenges. Computer Science & IT Research Journal. 2024;5(4):892-902.

[44] Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. Computer-aided prediction of pharmacokinetic (ADMET) properties. Dosage form design parameters: Elsevier; 2018. p. 731-55.

[45] Anjaneyulu B, Goswami S, Banik P, Chauhan V, Raghav N, Chinmay. Revolution of Artificial Intelligence in Computational Chemistry Breakthroughs. Chemistry Africa. 2024:1-17.

[46] Correia J, Capela J, Rocha M. DeepMol: An Automated Machine and Deep Learning Framework for Computational Chemistry. bioRxiv. 2024:2024.05. 27.595849.

[47] Panda P, Mohapatra R. Revolutionizing Patient Safety: Machine Learning and AI for the Early Detection of Adverse Drug Reactions and Drug-Induced Toxicity. Current Artificial Intelligence. 2024.

[48] Yang S, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. Artificial Intelligence Chemistry. 2023:100011.

[49] Kumar SA, Ananda Kumar TD, Beeraka NM, Pujar GV, Singh M, Narayana Akshatha HS, et al. Machine learning and deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry. Future Medicinal Chemistry. 2022;14(4):245-70.

[50] Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery. 2010;9(3):203-14.

[51] Rehan H. Advancing Cancer Treatment with AI-Driven Personalized Medicine and Cloud-Based Data Integration. Journal of Machine Learning in Pharmaceutical Research. 2024;4(2):1-40.

[52] Nothaft F, Power B. The Most Disruptive Near-Term Use of AI in Cancer Care: Patient Empowerment Through Software Agents. AI in Precision Oncology. 2024;1(5):256-76.

[53] Patel SK, George B, Rai V. Artificial intelligence to decode cancer mechanism: beyond patient stratification for precision oncology. Frontiers in Pharmacology. 2020;11:1177.

[54] Hays P, Hays P. The Genome in the Clinic and Boardroom: Biomarkers, Diagnosis, Treatment, and Education. Advancing Healthcare Through Personalized Medicine. 2021:525-57.

[55] Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC medical education. 2023;23(1):689.

[56] Apostolakis I. World Data in the Digital. Convergence of Population Health Management, Pharmacogenomics, and Patient-Centered Care. 2024:91.

[57] Xie Y, Lu L, Gao F, He S-j, Zhao H-j, Fang Y, et al. Integration of artificial intelligence, blockchain, and wearable technology for chronic disease management: a new paradigm in smart healthcare. Current Medical Science. 2021;41(6):1123-33.

[58] van Laar SA, Gombert-Handoko KB, Guchelaar H-J, Zwaveling J. Use of real-world data sources to evaluate cancer treatments: current practice and future perspectives. an(2023, October 12).19.

[59] Anuyah S, Singh MK, Nyavor H. Advancing clinical trial outcomes using deep learning and predictive modelling: Bridging precision medicine and patient-centered care. arXiv preprint arXiv:241207050. 2024.

[60] Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. PAIN®. 2010;149(2):177-93.

[61] Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends in pharmacological sciences. 2019;40(8):577-91.

[62] Van Norman GA. Decentralized clinical trials: the future of medical product development?∗. Basic to Translational Science. 2021;6(4):384-7.

[63] Davis S. DCT POSITION PAPER.

[64] Schork NJ. Artificial intelligence and personalized medicine. Precision medicine in Cancer therapy. 2019:265-83.

[65] Riad AKI, Barek MA, Rahman MM, Akter MS, Islam T, Rahman MA, et al., editors. Enhancing HIPAA Compliance in AI-driven mHealth Devices Security and Privacy. 2024 IEEE 48th Annual Computers, Software, and Applications Conference (COMPSAC); 2024: IEEE.

[66] Nguyen DC, Ding M, Pham Q-V, Pathirana PN, Le LB, Seneviratne A, et al. Federated learning meets blockchain in edge computing: Opportunities and challenges. IEEE Internet of Things Journal. 2021;8(16):12806-25.

[67] Raj R, Raja S, editors. Revolutionizing Healthcare: Blockchain's Transformative Applications for Data Security, Privacy, and Interoperability. 2024 IEEE 9th International Conference for Convergence in Technology (I2CT); 2024: IEEE.

[68] Nwebonyi N, McKay F. Exploring bias risks in artificial intelligence and targeted medicines manufacturing. BMC Medical Ethics. 2024;25(1):113.

[69] Cross JL, Choma MA, Onofrey JA. Bias in medical AI: Implications for clinical decision-making. PLOS Digital Health. 2024;3(11):e0000651.

[70] Fabris A. Algorithmic Fairness Datasets: Curation, Selection, and Applications. 2023.

[71] Felzmann H, Villaronga EF, Lutz C, Tamò-Larrieux A. Transparency you can trust: Transparency requirements for artificial intelligence between legal norms and contextual concerns. Big Data & Society. 2019;6(1):2053951719860542.

[72] Chinta SV, Wang Z, Zhang X, Viet TD, Kashif A, Smith MA, et al. Ai-driven healthcare: A survey on ensuring fairness and mitigating bias. arXiv preprint arXiv:240719655. 2024.

[73] Subbiah V. The next generation of evidence-based medicine. Nature medicine. 2023;29(1):49-58.

[74] Nikfal N. A DEVELOPMENT PROCESS FRAMEWORK FOR ARTIFICIAL INTELLIGENCE/MACHINE LEARNING (AI/ML)-BASED CONNECTED HEALTH INFORMATICS: Purdue University Graduate School; 2024.

[75] Mirakhori F, Niazi SK. Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective. Pharmaceuticals. 2025;18(1):47.

[76] Buzbee WW. Recognizing the regulatory commons: A theory of regulatory gaps. Iowa L Rev. 2003;89:1.

[77] Ain QU, Nazir R, Nawaz A, Shahbaz H, Dilshad A, Mufti IU, et al. Machine Learning Approach towards Quality Assurance, Challenges and Possible Strategies in Laboratory Medicine. Journal of Clinical and Translational Pathology. 2024;4(2):76-87.

[78] Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon. 2024.

[79] Khatoon A, Ullah A, Qureshi KN. AI Models and Data Analytics. Next Generation AI Language Models in Research: Promising Perspectives and Valid Concerns. 2024:45.

[80] Tawfik SM, Elhosseiny AA, Galal AA, William MB, Qansuwa E, Elbaz RM, et al. Health inequity in genomic personalized medicine in underrepresented populations: a look at the current evidence. Functional & Integrative Genomics. 2023;23(1):54.

[81] Zisis K, Pavi E, Geitona M, Athanasakis K. Real-world data: A systematic literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. medRxiv. 2023:2023.10. 18.23297151.

[82] Heavner SF, Kumar VK, Anderson W, Al-Hakim T, Dasher P, Armaignac DL, et al. Critical data for critical care: a primer on leveraging electronic health record data for research from society of critical care medicine's panel on data sharing and harmonization. Critical Care Explorations. 2024;6(11):e1179.

[83] Hulsen T. Sharing is caring—data sharing initiatives in healthcare. International journal of environmental research and public health. 2020;17(9):3046.

[84] Houtkoop BL, Chambers C, Macleod M, Bishop DV, Nichols TE, Wagenmakers E-J. Data sharing in psychology: A survey on barriers and preconditions. Advances in methods and practices in psychological science. 2018;1(1):70-85.

[85] Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. Nature Machine Intelligence. 2020;2(10):573-84.

[86] Samek W, Montavon G, Lapuschkin S, Anders CJ, Müller K-R. Explaining deep neural networks and beyond: A review of methods and applications. Proceedings of the IEEE. 2021;109(3):247-78.

[87] Ng JY, Cramer H, Lee MS, Moher D. Traditional, complementary, and integrative medicine and artificial intelligence: Novel opportunities in healthcare. Integrative Medicine Research. 2024;13(1):101024.

[88] Tiwari R. Explainable ai (xai) and its applications in building trust and understanding in ai decision making. International J Sci Res Eng Manag. 2023;7:1-13.

[89] GUDE S, GUDE YS. The synergy of artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs. Translational and Regulatory Sciences. 2024;6(2):37-45.

[90] Taribagil P, Hogg HJ, Balaskas K, Keane PA. Integrating artificial intelligence into an ophthalmologist's workflow: obstacles and opportunities. Expert Review of Ophthalmology. 2023;18(1):45-56.

[91] Mohamed Ajmal A, Birhare S. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL INDUSTRY THE FUTURE. artificial intelligence.6:8.

[92] Kettinger WJ, Teng JT, Guha S. Business process change: a study of methodologies, techniques, and tools. MIS quarterly. 1997:55-80.

[93] Gillani F, Chatha KA, Jajja SS, Cao D, Ma X. Unpacking Digital Transformation: Identifying key enablers, transition stages and digital archetypes. Technological Forecasting and Social Change. 2024;203:123335.

[94] Pennington D, Ebert-Uphoff I, Freed N, Martin J, Pierce SA. Bridging sustainability science, earth science, and data science through interdisciplinary education. Sustainability Science. 2020;15:647-61.

[95] Chatterjee J. Strategy, human capital investments, business-domain capabilities, and performance: a study in the global software services industry. Strategic Management Journal. 2017;38(3):588-608.

[96] Banerjee D, Rajput D, Banerjee S, Saharan VA. Artificial intelligence and its applications in drug discovery, formulation development, and healthcare. Computer Aided Pharmaceutics and Drug Delivery: An Application Guide for Students and Researchers of Pharmaceutical Sciences: Springer; 2022. p. 309-80.

[97] Pei Z. Computer-aided drug discovery: From traditional simulation methods to language models and quantum computing. Cell Reports Physical Science. 2024;5(12).

[98] Hassija V, Chamola V, Mahapatra A, Singal A, Goel D, Huang K, et al. Interpreting black-box models: a review on explainable artificial intelligence. Cognitive Computation. 2024;16(1):45-74.

[99] Ahmadi A, RabieNezhad Ganji N. AI-driven medical innovations: transforming healthcare through data intelligence. International Journal of BioLife Sciences (IJBLS). 2023;2(2):132-42.

[100] Verma A, Rao K, Eluri V, Sharma Y. Regulating AI in public health: systems challenges and perspectives. ORF Occasional Paper. 2020;261.

[101] Schuhmacher A, Haefner N, Honsberg K, Goldhahn J, Gassmann O. The dominant logic of Big Tech in healthcare and pharma. Drug Discovery Today. 2023;28(2):103457.

[102] Pedro F, Subosa M, Rivas A, Valverde P. Artificial intelligence in education: Challenges and opportunities for sustainable development. 2019.

[103] Shneiderman B. Bridging the gap between ethics and practice: guidelines for reliable, safe, and trustworthy human-centered AI systems. ACM Transactions on Interactive Intelligent Systems (TiiS). 2020;10(4):1-31.

[104] Adel A, Alani NH. Human-Centric Collaboration and Industry 5.0 Framework in Smart Cities and Communities: Fostering Sustainable Development Goals 3, 4, 9, and 11 in Society 5.0. Smart Cities. 2024;7(4):1723.

[105] Mehl G, Vasudevan L, Gonsalves L, Berg M, Seimon T, Temmerman M, et al. Harnessing mHealth in low-resource settings to overcome health system constraints and achieve universal access to healthcare. Behavioral healthcare and technology: using science-based innovations to transform practice. 2014;239.

[106] Rashid AB, Kausik AK. AI revolutionizing industries worldwide: A comprehensive overview of its diverse applications. Hybrid Advances. 2024:100277.

[107] Ebulue CC, Ekkeh OV, Ebulue OR, Ekesiobi CS. Leveraging machine learning for vaccine distribution in resource-limited settings: A synthesis of approaches. International Medical Science Research Journal. 2024;4(5):544-57.

[108] Nwankwo EI, Emeihe EV, Ajegbile MD, Olaboye JA, Maha CC. Integrating telemedicine and AI to improve healthcare access in rural settings. International Journal of Life Science Research Archive. 2024;7(1):059-77.

[109] Adekugbe AP, Ibeh CV. Innovating service delivery for underserved communities: leveraging data analytics and program management in the US context. International Journal of Applied Research in Social Sciences. 2024;6(4):472-87.

[110] Parker RM, Ratzan S. Our future with democratization of health requires health literacy to succeed. American Behavioral Scientist. 2019;63(7):948-54.